newsfilter
← Latest News
GlobeNewswire·

Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV

Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially in the group receiving low-dose nivolumab with the heterologous